Journal of Clinical Endocrinology & Metabolism, Vol 79, 1141-1146, Copyright © 1994 by Endocrine Society

ARTICLES

Growth hormone secretion in critical illness: effect of dopamine

G Van den Berghe, F de Zegher, P Lauwers and JD Veldhuis
Department of Intensive Care Medicine, University of Leuven, Belgium.

The catabolic state is a major contributor to the morbidity and mortality of critical illness. The underlying mechanism is poorly understood. We examined the endogenous secretion of an anabolic protein, GH, and studied the effect exerted on its secretion by dopamine, a catecholamine that is frequently administered for cardiovascular purposes in critical care. In a randomized controlled study of critically ill adult polytrauma patients (n = 11), we evaluated the effect of prolonged (83- to 296-h) dopamine infusion (5 micrograms/kg.min, iv) on the dynamics of GH secretion and on serum insulin-like growth factor-I, cortisol, and insulin concentrations. The effect of brief (15- to 21-h) dopamine administration was documented in an additional randomized controlled cross-over study involving nine patients. The GH profiles, obtained by blood sampling every 20 min for 9 h during 2 consecutive nights, were examined by deconvolution analysis. GH release was found to be exclusively pulsatile in all patients. Prolonged and brief dopamine infusions appeared to have similar effects. Twenty-four hours before initiation or after withdrawal of dopamine infusion, mean serum GH concentrations, mean secretion rate, amount of GH per secretory burst, and secretory burst amplitude were low, but, respectively, a median of 17% (P = 0.028), 36% (P = 0.046), 40% (P = 0.008), and 94% (P = 0.002) higher than those during dopamine infusion. After dopamine withdrawal, increased GH secretion was detectable within 3 h. Dopamine's effect on GH release was specific, as this agent had no discernable effect on the elevated serum cortisol and insulin concentrations or the low plasma insulin- like growth factor-I levels within 24 h. In conclusion, the present data suggest that pulsatile GH secretion is low during critical illness and that dopamine infusion further attenuates GH secretion through amplitude modulation, possibly as a result of a direct inhibitory action on the somatotropes. The latter iatrogenic effect might further aggravate the catabolic state of critical illness.

This article has been cited by other articles:

				D. Jones and R. Bellomo Renal-Dose Dopamine: From Hypothesis to Paradigm to Dogma to Myth and, Finally, Superstition? J Intensive Care Med, July 1, 2005; 20(4): 199 - 211. [Abstract] [PDF]

				J. O. Friedrich, N. Adhikari, M. S. Herridge, and J. Beyene Meta-Analysis: Low-Dose Dopamine Increases Urine Output but Does Not Prevent Renal Dysfunction or Death Ann Intern Med, April 5, 2005; 142(7): 510 - 524. [Abstract] [Full Text] [PDF]

				D. Mesotten, P. J. Wouters, R. P. Peeters, K. V. Hardman, J. M. Holly, R. C. Baxter, and G. Van den Berghe Regulation of the Somatotropic Axis by Intensive Insulin Therapy during Protracted Critical Illness J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3105 - 3113. [Abstract] [Full Text] [PDF]

				Y. A. Debaveye and G. H. Van den Berghe Is There Still a Place for Dopamine in the Modern Intensive Care Unit? Anesth. Analg., February 1, 2004; 98(2): 461 - 468. [Abstract] [Full Text] [PDF]

				C. L. Holmes and K. R. Walley Bad Medicine: Low-Dose Dopamine in the ICU Chest, April 1, 2003; 123(4): 1266 - 1275. [Abstract] [Full Text] [PDF]

				M. Slevin, J. Krupinski, A. Slowik, P. Kumar, A. Szczudlik, and J. Gaffney Serial Measurement of Vascular Endothelial Growth Factor and Transforming Growth Factor-{beta}1 in Serum of Patients With Acute Ischemic Stroke Stroke, August 1, 2000; 31(8): 1863 - 1870. [Abstract] [Full Text] [PDF]

				G. Van den Berghe, R. C. Baxter, F. Weekers, P. Wouters, C. Y. Bowers, and J. D. Veldhuis A Paradoxical Gender Dissociation within the Growth Hormone/Insulin-Like Growth Factor I Axis during Protracted Critical Illness J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 183 - 192. [Abstract] [Full Text]

				G. Van den Berghe, P. Wouters, F. Weekers, S. Mohan, R. C. Baxter, J. D. Veldhuis, C. Y. Bowers, and R. Bouillon Reactivation of Pituitary Hormone Release and Metabolic Improvement by Infusion of Growth Hormone-Releasing Peptide and Thyrotropin-Releasing Hormone in Patients with Protracted Critical Illness J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1311 - 1323. [Abstract] [Full Text]

				G. Van den Berghe, P. Wouters, L. Carlsson, R. C. Baxter, R. Bouillon, and C. Y. Bowers Leptin Levels in Protracted Critical Illness: Effects of Growth Hormone-Secretagogues and Thyrotropin-Releasing Hormone J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3062 - 3070. [Abstract] [Full Text]

				G. Van den Berghe, F. de Zegher, R. C. Baxter, J. D. Veldhuis, P. Wouters, M. Schetz, C. Verwaest, E. Van der Vorst, P. Lauwers, R. Bouillon, et al. Neuroendocrinology of Prolonged Critical Illness: Effects of Exogenous Thyrotropin-Releasing Hormone and Its Combination with Growth Hormone Secretagogues J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 309 - 319. [Abstract] [Full Text]

				M. Scacchi, A. I. Pincelli, A. Caumo, P. Tomasi, G. Delitala, G. Baldi, and F. Cavagnini Spontaneous Nocturnal Growth Hormone Secretion in Anorexia Nervosa J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3225 - 3229. [Abstract] [Full Text] [PDF]

				S. Schwab, M. Spranger, S. Krempien, W. Hacke, and M. Bettendorf Plasma Insulin-like Growth Factor I and IGF Binding Protein 3 Levels in Patients With Acute Cerebral Ischemic Injury Stroke, September 1, 1997; 28(9): 1744 - 1748. [Abstract] [Full Text]

				F. d. Zegher, I. Francois, m. van helvoirt, and g. van den berghe Small as Fetus and Short as Child: From Endogenous to Exogenous Growth Hormone J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2021 - 2026. [Full Text] [PDF]

				G. Van den Berghe, F. de Zegher, J. D. Veldhuis, P. Wouters, M. Awouters, W. Verbruggen, M. Schetz, C. Verwaest, P. Lauwers, R. Bouillon, et al. The Somatotropic Axis in Critical Illness: Effect of Continuous Growth Hormone (GH)-Releasing Hormone and GH-Releasing Peptide-2 Infusion J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 590 - 599. [Abstract] [Full Text] [PDF]